FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Algernon Pharmaceuticals Inc. (the "**Issuer**" or the "**Company**").

Trading Symbol: AGN

Number of Outstanding Listed Securities: 110,057,080

Date: June 3, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   The Company continues to advance with its planned first Phase 2 clinical trial for idiopathic pulmonary fibrosis and chronic cough.

   The Company is developing a clinical program for acute lung injury, specifically for COVID-19, which includes preparing for Phase 2 clinical trials in multiple jurisdictions. `

   The Company is supporting an investigator-led study of Ifenprodil in a COVID-19 Phase 2 in South Korea. The study has received ethics and regulatory approval.

   The Company has also received a no objection letter from Heath Canada for a Phase 2b/3 multinational trial in Canada and has filed an Investigational New Drug Application with the U.S. FDA and has sought ethics approval in Australia.

2. Provide a general overview and discussion of the activities of management.

   On May 06, 2020, the Company announced that it has received ethics approval from the Royal Brisbane & Women's Hospital, Human Research Ethics Committee for the Company's planned Phase 2 Idiopathic Pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil), an NMDA receptor antagonist.

   On May 13, 2020 the Company announced that it closed its previously announced private placement offering of special warrants of the Company (the "Special Warrants"), which included the exercise of the over-allotment option, pursuant to which the Company issued 19,605,285 Special Warrants at a price of $0.35 per Special Warrant, for aggregate gross proceeds of approximately $6,861,849.

On May 15, 2020 the Company announced that it has submitted for ethics approval in Australia for its planned multinational Phase 2b/3 study of its re-purposed drug NP-120 (Ifenprodil) for COVID-19. The ethics submission was made at Princess Alexandra Hospital located in Brisbane, Queensland.

On May 26, 2020 the Company announced that it has submitted an Investigational New Drug (IND) application with the U.S. FDA for its planned multinational Phase 2b/3 study of its re-purposed drug NP-120 (Ifenprodil) as a potential therapeutic treatment for patients with COVID-19. Ifenprodil is an NMDA receptor antagonist.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the dispositions was to a Related Person of the Issuer and provide details of the relationship.

None.

7. Describe the acquisition of new customers or loss of customers.

None.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None

10. Report on any labour disputes and resolutions of those disputes if applicable.

None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

13. Provide details of any securities issued and options or warrants granted.

Security	**Number Issued**	**Details of Issuance**	**Use of Proceeds**
Common Shares	320,160	Issued 320,160 common shares as a result of 320,160 warrants with an exercise price of $0.12 being exercised for proceeds of $38,419.20	For general corporate purposes.
Common Shares	20,680	Issued 14,883 common shares and 14,883 warrants as result of 14,883 finders' warrants with an exercise price of $0.085 being exercised for proceeds of $1,265.05. Each finders' warrant entitled the holder to purchase a common share and warrant for $0.085. The warrant may be exercised for $0.12.	For general corporate purposes.

14. Provide details of any loans to or by Related Persons.

None.

15. Provide details of any changes in directors, officers or committee members.

None.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. Please to the "Risks Related To The Business" section of the Issuer's management discussion and analysis for the year ended August 31, 2019, which is available on SEDAR at www.sedar.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: June 3, 2020

Christopher Moreau
Name of Director or Senior Officer

"Christopher Moreau"
Signature

CEO
Official Capacity

Issuer Details Name of Issuer Algernon Pharmaceuticals Inc.	For Month End May 31, 2020	Date of Report YY/MM/D 2020/06/03
Issuer Address Suite 915 – 700 West Pender Street		
City/Province/Postal Code Vancouver, BC V6C 1G8	Issuer Fax No. NA	Issuer Telephone No. (604) 646-1553
Contact Name Christopher J. Moreau	Contact Position CEO	Contact Telephone No. (604) 398-4175 ext. 701
Contact Email Address info@algernonpharmaceuticals.com	Web Site Address https://algernonpharmaceuticals.com/	